Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids

Journal of the Royal Society of Medicine, Supplement

Volumn 95, Issue 42, 2002, Pages 46-53

  De Graaf, Jacqueline ^a   Veerkamp, Mario J ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B100; FATTY ACID; INSULIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FAMILIAL DISEASE; FAMILIAL HYPERLIPEMIA; FATTY ACID METABOLISM; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID METABOLISM; PATHOGENESIS; PHENOTYPE; RISK FACTOR;

ADIPOSE TISSUE; BLOOD PROTEINS; CHOLESTEROL ESTERASE; COMPLEMENT C3A; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN LIPASE; OBESITY; PHENOTYPE;

EID: 0036347066     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia
2. Inheritance of combined hyperlipoproteinemia: Evidence for a new lipoprotein phenotype
3. Family study of serum lipids and lipoproteins in coronary heart-disease
4. Metabolic and genetic aspects of familial combined hyperlipidemia with emphasis on LDL heterogeneity
5. Defects of lipoprotein metabolism in familial combined hyperlipoproteinemia
6. Novel genes for familial combined hyperlipidemia
7. Diagnosis of familial combined hyperlipidemia (FCH) based on lipid phenotype in 32 families: Results of a 5 years follow-up study
8. A proposal to redefine familial combined hyperlipidemia
9. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia
10. Lack of evidence for linkage between low-density lipoprotein subclass phenotypes and the apolipoprotein B locus in familial combined hyperlipidemia
11. Lipoproteins and lipid transport
12. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia
13. Familial combined hyperlipidemia and abnormal lipoprotein lipase
14. The lipoprotein lipase (Asn291Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidemia
15. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families
16. Release of endothelial lipoprotein lipase by plasma lipoproteins and free fatty acids
17. Insulin increases the synthetic rate and messenger RNA level of lipoprotein lipase in isolated rat adipocytes
18. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo
19. Insulin resistance and lipoprotein metabolism
20. The dense LDL phenotype: Association with plasma lipoprotein levels, visceral obesity and hyperinsulinemia in men
21. Non-obese patients with familial combined hyperlipidemia are insulin resistant as compared with their non-affected relatives
22. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia
23. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: A precursor defect for dyslipidemia?
24. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients
25. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance
26. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance
27. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion
28. Effects of tumor necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism in newly-differentiated human fat cells in cell culture
29. Serum leptin is elevated out of proportion to the body mass index in adolescent females with familial combined hyperlipidemia
30. The glucose fatty acid cycle and its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
31. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans
32. Glucose intolerance in familial combined hyperlipidemia
33. Abdominal obesity and its metabolic complications: Implications for the risk of ischaemic heart disease
34. Relationship of insulin sensitivity and apoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia
35. A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in FCH
36. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation stimulating protein and insulin
37. The adipocyte, fatty acid trapping, and atherogenesis
38. Purification and characterization and acylation-stimulating protein
39. Of mice and men (and women) and the acylation-stimulating protein pathway
40. Impaired response to fibroblasts in patients with hyperapobetalipoproteinemia to acylation stimulating protein
41. Plasma acylation stimulating protein (ASP) in patients with hyperapoB
42. Genetic deficiency of acylation stimulating protein (ASP/C3adesArg) does not cause hyperapobetalipoproteinemia in mice
43. Plasma acylation stimulating protein in coronary artery disease
44. Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia
45. The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers
46. Metabolic response of acylation stimulating protein to an oral fat load
47. Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period
48. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia
49. Reduced hormone-sensitive lipase activity is not a major metabolic defect in finnish familial combined hyperlipidemia families
50. The hormone sensitive lipase gene in familial combined hyperlipidemia and insulin resistance
51. Is familial combined hyperlipidaemia a genetic disorder of adipose tissue
52. Role of endogenous fatty acids in the control of hepatic gluconeogenesis
53. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia